ERBB2 and metastatic neoplasm: Instead, for metastatic disease, median overall survival is 4–5 years for the hormone receptor-positive subgroup, 5 years for HER2-positive disease, where the prognosis is remarkably improved with the specific therapies, and 10–13 months for triple negative [3].